Skip to content

Medical emergency? What to do

FDA staff questions Cephalon drug for ADHD

3-RXPublished March 23, 20062 min read

Key points

  • Food and Drug Administration staff reviewers have raised questions about Cephalon Inc.'s bid to market its Sparlon drug to treat attention deficit hyperactivity disorder (ADHD), according to documents made public on Wednesday.
  • The drugmaker's shares fell $4.31, or 6 percent, to $67.55 on the Nasdaq in morning trading.
  • "Despite the demonstration of clinical efficacy, the safety profile demonstrates increased and, in this reviewers opinion, unacceptable risks to children and adolescents," he said in a memo dated Sept.
  • "The incidence... in general is reported to be low, only a few cases per million.

Some U.S. Food and Drug Administration staff reviewers have raised questions about Cephalon Inc.'s bid to market its Sparlon drug to treat attention deficit hyperactivity disorder (ADHD), according to documents made public on Wednesday.

The staff reports were released ahead of an FDA advisory panel meeting on Thursday to discuss the new use of the drug, which is already sold as Provigil to treat sleep disorders.

The drugmaker's shares fell $4.31, or 6 percent, to $67.55 on the Nasdaq in morning trading.

In October 2005, the agency told the company Sparlon could be approved pending certain conditions. But one month earlier, a staff reviewer said the drug carries serious risks and should not be approved for ADHD, according to documents posted on the FDA Web site at http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4212B1-index.htm.

"Despite the demonstration of clinical efficacy, the safety profile demonstrates increased and, in this reviewers opinion, unacceptable risks to children and adolescents," he said in a memo dated Sept. 26, 2005.

More recently, another reviewer said he was concerned about the incidence of serious skin rashes, including erythema multiforme and Stevens Johnson Syndrome, found in people taking the medicine.

"The incidence... in general is reported to be low, only a few cases per million. Therefore, the finding of a few cases resembling EM/SJS within the population studied is of concern," FDA medical officer Joseph Porres wrote in a Feb. 27 memo.

Porres said he reviewed data from 933 patients in completed trials and another 533 in an ongoing study as well as post-marketing reports. Six patients appeared to have the serious rashes, another 15 had suggested cases, while 16 appeared to have symptoms but could not be diagnosed.

Cephalon, in other documents released, said its review of clinical studies found a "small increase" of rashes in children and adolescents taking the drug compared to those taking a placebo.

Because of uncertainties diagnosing the skin problems, "the serious nature of the adverse events reported warrant communication of the potential risk through appropriate labeling," the company said.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.